Caner Saygin, MD
@canersaygin.bsky.social
Leukemologist at the University of Chicago
We are thankful to the funding sources that supported the key personnel and helped us complete this project.
@ash.hematology.org, @preventcancer.org, LLS and CRF
@ash.hematology.org, @preventcancer.org, LLS and CRF
July 16, 2025 at 8:25 PM
We are thankful to the funding sources that supported the key personnel and helped us complete this project.
@ash.hematology.org, @preventcancer.org, LLS and CRF
@ash.hematology.org, @preventcancer.org, LLS and CRF
Altogether, serial monitoring of CH may complement MRD assessment in myeloma to identify individuals who are candidates for treatment de-escalation due to risk for SPHM.
Dynamic CH assessment should be further validated as a potential endpoint for future interventional CH trials.
Dynamic CH assessment should be further validated as a potential endpoint for future interventional CH trials.
July 16, 2025 at 8:11 PM
Altogether, serial monitoring of CH may complement MRD assessment in myeloma to identify individuals who are candidates for treatment de-escalation due to risk for SPHM.
Dynamic CH assessment should be further validated as a potential endpoint for future interventional CH trials.
Dynamic CH assessment should be further validated as a potential endpoint for future interventional CH trials.
Patients with progressive TP53-mutant CH clones progressed to therapy-related ALL or myeloid neoplasms, while stable clones had lower leukemogenic potential. The data suggest that serial monitoring is more informative than cross-sectional assessment of CH in pts receiving MM tx.
July 16, 2025 at 8:11 PM
Patients with progressive TP53-mutant CH clones progressed to therapy-related ALL or myeloid neoplasms, while stable clones had lower leukemogenic potential. The data suggest that serial monitoring is more informative than cross-sectional assessment of CH in pts receiving MM tx.
The meticulous work co-led by Jen Cooperrider and Arda Karaoglu revealed that ongoing lenalidomide maintenance selectively expands TP53-mutant CH clones as opposed to age-related CH (DTA muts).
Discontinuation of lenalidomide led to stability or regression of TP53-mutant CH.
Discontinuation of lenalidomide led to stability or regression of TP53-mutant CH.
July 16, 2025 at 8:11 PM
The meticulous work co-led by Jen Cooperrider and Arda Karaoglu revealed that ongoing lenalidomide maintenance selectively expands TP53-mutant CH clones as opposed to age-related CH (DTA muts).
Discontinuation of lenalidomide led to stability or regression of TP53-mutant CH.
Discontinuation of lenalidomide led to stability or regression of TP53-mutant CH.
We needed a sensitive NGS assay to monitor clones in pts treated with R or KRd maintenance (ATLAS) and in pts who stopped R after MRD negativity (MRD2STOP).
This was achieved in collaboration with @alexbick.bsky.social at Vanderbilt, using their targeted CH panel.
This was achieved in collaboration with @alexbick.bsky.social at Vanderbilt, using their targeted CH panel.
July 16, 2025 at 8:10 PM
We needed a sensitive NGS assay to monitor clones in pts treated with R or KRd maintenance (ATLAS) and in pts who stopped R after MRD negativity (MRD2STOP).
This was achieved in collaboration with @alexbick.bsky.social at Vanderbilt, using their targeted CH panel.
This was achieved in collaboration with @alexbick.bsky.social at Vanderbilt, using their targeted CH panel.
To understand the impact of lenalidomide on evolution of therapy-related CH, we studied prospectively obtained samples from two major MM trials (ATLAS and MRD2STOP), run by
Ben Derman, Andrzej Jakubowiak and Jen Cooperrider.
Ben Derman, Andrzej Jakubowiak and Jen Cooperrider.
July 16, 2025 at 8:09 PM
To understand the impact of lenalidomide on evolution of therapy-related CH, we studied prospectively obtained samples from two major MM trials (ATLAS and MRD2STOP), run by
Ben Derman, Andrzej Jakubowiak and Jen Cooperrider.
Ben Derman, Andrzej Jakubowiak and Jen Cooperrider.
Nice data but OS curves do not seem to have a plateau. They keep going down. I still don`t think CAR-T cures ALL. Unlike allo curves below showing ~1/3 of pts may be cured. www.nature.com/articles/s41...
March 23, 2025 at 6:18 AM
Nice data but OS curves do not seem to have a plateau. They keep going down. I still don`t think CAR-T cures ALL. Unlike allo curves below showing ~1/3 of pts may be cured. www.nature.com/articles/s41...
Interesting. Sounds like this may be best classified as T/myeloid MPAL (bilineal).
November 23, 2024 at 8:37 PM
Interesting. Sounds like this may be best classified as T/myeloid MPAL (bilineal).
Do they share a fusion (e.g. ETV6::ABL1)?
Myeloid mutations are very common in T-ALL, especially with age.
T-ALL and AML can sometimes mingle/differentially interpreted by different pathologists. They are more similar than different, evidenced by T-ALL response to myeloid drugs (Aza/ven, IDH inh)
Myeloid mutations are very common in T-ALL, especially with age.
T-ALL and AML can sometimes mingle/differentially interpreted by different pathologists. They are more similar than different, evidenced by T-ALL response to myeloid drugs (Aza/ven, IDH inh)
November 23, 2024 at 2:08 AM
Do they share a fusion (e.g. ETV6::ABL1)?
Myeloid mutations are very common in T-ALL, especially with age.
T-ALL and AML can sometimes mingle/differentially interpreted by different pathologists. They are more similar than different, evidenced by T-ALL response to myeloid drugs (Aza/ven, IDH inh)
Myeloid mutations are very common in T-ALL, especially with age.
T-ALL and AML can sometimes mingle/differentially interpreted by different pathologists. They are more similar than different, evidenced by T-ALL response to myeloid drugs (Aza/ven, IDH inh)